Cardiovascular

The reduced mortality risk was not seen in patients who did not have diabetes before surgery. But in those who did, the results were dramatic.

Patients often stop statin treatment following an adverse reaction; however, new research finds an association between continued statin prescriptions after an adverse reaction and a decreased incidence of death and cardiovascular events.

Many accountable care organizations participating in the Medicare Shared Savings Program focus on disease control and medication use, but a new study published in JAMA Cardiology has found that the programs have not made any meaningful changes in medication use or adherence.

Coverage from the first of 3 Peer Exchangeâ„¢ discussions from the Diabetes Stakeholders Summit.

There is an association between the presence of cardiovascular risk factors in adolescence and a lower cognition later in life, regardless of the exposure experienced during adulthood.

A new vaccine may be able to reduce low-density lipoprotein (LDL) cholesterol and, therefore, protect people against the risk of cardiovascular disease.

New results from a meta-analysis reveal a decrease in the excess risk of cardiovascular events in patients with rheumatoid arthritis (RA) since the start of the 21st century.

Liraglutide, a GLP-1 receptor agonist sold as Victoza, becomes the second diabetes therapy to receive the cardiovascular indication.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Cardiovascular outcomes trials and a photography ban that dominated social media were big news at the 77th Scientific Sessions of the American Diabetes Association.

The study's lead author said that complications from cardiovascular disease remain an unmet clinical challenge in type 2 diabetes.

While statins are primarily used to lower cholesterol, they are also associated with improved heart structure and function, according to research presented at EuroCMR 2017, which was held by the European Society of Cardiology, May 25-27, in Prague, Czech Republic.

Patients with peripheral artery disease can now have supervised exercise therapy covered by Medicare, according to a recent announcement by CMS.

While regulators long ago saw enough cardiovascular safety data to approve insulin degludec, full trial results will be presented June 12 at the American Diabetes Association Scientific Sessions in San Diego.